What question did this study set out to answer?

This research aims to evaluate the efficacy and safety of the AAV8-tATP7B vector for treating Wilson’s disease.

March 7, 2026Clinical and Molecular Hepatology0 citationsOpen Access

Preclinical pharmacology and toxicology study of an AAV8-tATP7B vector for Wilson’s disease

This research aims to evaluate the efficacy and safety of the AAV8-tATP7B vector for treating Wilson’s disease.
Conducted preclinical pharmacology and toxicology assessments of AAV8-tATP7B.
Evaluated vector efficacy in relevant animal models.
Assessed safety profiles through toxicological studies.
AAV8-tATP7B demonstrated effective targeting and correction of Wilson’s disease pathology.
Safety assessments indicated a favorable profile with minimal adverse effects.

These results establish the efficacy and safety profile of AAV8-tATP7B and provide the rationale for its clinical translation in patients with WD.

AI से पूछें

Bookmark

View Full Paper

AI से पूछें

Bookmark

View Full Paper